SynBioBeta 2027 Super Early Bird pricing is available through Friday, June 15.
Join the AIxBio founders, biopharma leaders, investors, and startups building the future of biology.
Presenting sponsor: Pumpkinseed
May 3–6, 2027 | San Jose, CA
Lock in your pass early.
https://t.co/oDyS6XJ0Q4
🚨 Exclusive: Saku Biosciences and Sable Fermentation, Inc. have signed an exclusive US strategic alliance agreement, putting strain engineering and scale-up under one contract. @SynBioBeta has the story:👇
Most microbial products pass through four stages on the way to market:
1. Strain development: engineering and screening a microbe for titer, rate and yield.
2. Upstream processing: fermentation development and scale-up.
3. Downstream processing: recovery, separation, concentration and drying.
4. Formulation: turning the material into something a customer can apply or ship.
Different vendors usually handle these stages, and each handoff means a new MSA and a new tech transfer.
The costliest gap is between stages 1 and 2. Strains are usually screened in well plates or shake flasks, where oxygen transfer, mixing and substrate feeding look nothing like a stirred-tank bioreactor. The best performer on the bench is often not the best performer in the tank, and that mismatch shows up months later at pilot scale.
Saku (strain development)
Saku's PicoShells, developed in @dinodicarlo lab at @UCLA and published in PNAS, are picoliter-scale hydrogel particles with a porous shell. Each one holds a single cell and its descendants, fenced in but exposed to the surrounding media. That means more than a million clonal colonies can grow together in real production conditions and be sorted on standard equipment, up to 10 million in a day. Mark van Zee and John Alden picked Sable specifically because they knew what was missing was the scale up peice.
Sable (upstream, downstream and formulation)
Sable's Wake Forest, NC pilot plant runs submerged fermentation from 1L to 200L, with downstream processing including tangential flow filtration, centrifugation and spray drying, plus formulation and analytics. Its team comes largely from ag biologicals, including AgBiome, Marrone BioInnovations and Pasteuria Bioscience, Inc.
Put together, Saku selects strains in the kind of environment Sable will run them in, and the results from Sable's runs go straight back into the next round of screening.
"We saw an opportunity to solve one of the biggest inefficiencies in bioprocess development: the disconnect between strain selection and the conditions a strain will ultimately face at scale," said Toni Bucci, Ph.D., founder and CEO of Sable Fermentation.
Sable manages the customer relationship end to end. Neither company takes back-end royalties or claims on customer IP. They are paid through success fees.
The arrangement is aimed at food, agriculture and industrial biotech companies moving from lab scale toward contract manufacturing.
A microbiome model trained without human samples was still transferred to human-gut prediction tasks.
Outpost Bio trained Waypoint on 539,308 microbiome samples, then open-sourced the model, data, and benchmark through @huggingface.
https://t.co/IOFUw4zI8Q
Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬
https://t.co/uNrxaa71hj
AI-powered molecular design is expanding beyond drug discovery.
@dsmfirmenich is partnering with Boltz to combine biomolecular foundation models with extensive taste and odor receptor data—supporting the prediction and design of new scent and flavor molecules.
https://t.co/ZoGjVBtMPx
Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬
https://t.co/uNrxaa7z6R
Europe’s largest bacterial cellulose plant is coming to Germany.
@BIOWEG_UG plans to produce up to 10,000 tonnes annually of biodegradable ingredients made from local industrial side streams, with construction beginning in Q4 2026 and commercial volumes expected in 2028.
https://t.co/KwT04x8k78
Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬
https://t.co/uNrxaa71hj
@inductivebio has launched Indy, an AI assistant for medicinal chemistry.
It handles assay QC, SAR analysis, synthesis tracking, FEP and dose projection. In Inductive’s 84-curve evaluation, Indy reached 89% accuracy and the company says its scientists doubled productivity.
https://t.co/6Zms4qqEGG
Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬
https://t.co/uNrxaa71hj
FairJourney Bio has selected @SapioSciences to unify antibody discovery data across its Porto, Cambridge and San Diego sites.
Its LIMS, ELN and Elain AI tools will replace disconnected records and manual reporting, potentially returning up to 40% of staff time to science.
https://t.co/aChQJaMCgG
Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬
https://t.co/uNrxaa7z6R
🚀 @ycombinator. 🤝 An acquisition. 💰 $2.6M+ in funding and fellowships. That's our 2026 @SynBioBeta Next-Gen Bio-leader alumni just 4 months post conference; 2027 applications just opened 👀
🔗 https://t.co/q4isaW77FM
Next-Gen BioLeaders is a one-day program at SynBioBeta for students, postdocs, early-career academics and pre-seed founders in programmable biology. You spend the day with biotech investors and founders who have built companies from scratch: VC masterclasses, small-group mentorship, a founders lunch and curated introductions.
Here's what the 2026 cohort has done since May:
☘️ Nitroduck | Matej Zámečník, Matúš Grieš, Miroslav Rosputinský
Just got into Y Combinator (F26).
🛡️ TwentyTwo (YC S25) | @_harm0n, Evan Seeyave
Acquired by @LatchBio. They now lead Latch Biosecurity.
🧪 @cypherbio | @yaoyuyang
$2M seed led by @MaCVentureCap for an AI operating system for lab work.
☀️ Solio Bio | Nathan Paumier
Came out of stealth backed by Replicator VC. @jaykeasling just joined the scientific advisory board.
🫧 Flux Bio | Marika Ziesack
Launched as a @Harvard / @wyssinstitute spinout to fix gas transfer in fermentation.
🦠 Outpost Bio | Jenny Yang
Released Waypoint, a foundation model for microbial communities.
💾 BioCompute | @anagha_dna
Moved from Bengaluru to San Francisco to build DNA data storage chips.
🧬 LUCAI Bio | Joaquin Ortiz Masllorens
Won the South Summit pitch competition and Best Entrepreneur at the Puentes de Talento accelerator.
🐛 Yeast Bay Bio | Nazzy Pakpour
Raised from the California Innovation Fund for yeast-based pest control.
🔬 On the research side:
Sam Oliveira won a $302K @DARPA Director's Fellowship, one of seven awarded.
🪴 Nolux | Elizabeth Hann joined @activatefellows with her company Nolux and leads a Wyss Validation Project.
@YeshDoctor was co-first author on a @NatureBiotech paper.
If you're building in biology and want to meet the people who fund and scale it, this is your day. Selected participants receive a complimentary conference pass and up to $500 travel support.
🔗 https://t.co/q4isaW77FM
FY2027 starts October 1. If federal funding is part of your plan, @EverGlade and QNova LifeSciences are running a webinar Wednesday on what the landscape looks like.
Agency priorities across DoD, HHS, and DOE, how to prep at each phase from proposal through post-award, and where regulatory and commercialization strategy fit in.
Sept 24, 12pm ET
https://t.co/wKWe6Nkj3o
A £700K @ARIA_research grant will support Bitrobius Genetics and @MRC_MBU in adapting Gentrafix™ for mitochondrial DNA delivery.
The project targets the double-membrane barrier that has constrained mitochondrial gene therapy.
https://t.co/MFiiOQpssc
Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬
https://t.co/uNrxaa71hj
@NSF is investing $20M in a two-year pilot led by @UCF to help deep-tech small businesses cross the commercialization gap.
The program will test funding, mentorship and investor connections while identifying which approaches best move federally backed technologies to market.
https://t.co/VDseXwQ9w3
Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬
https://t.co/uNrxaa7z6R
Engineered marine bacteria increased olivine dissolution by up to 3.1× in pilot reactors using seawater and renewable acetate. The system weathered 4 kg of olivine and removed a measured 0.50 g of CO₂ from the air per day.
https://t.co/Aiekpa4R1E
Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬
https://t.co/uNrxaa7z6R
Five pharmas trained OpenFold3 on 20,167 private structures without pooling the data. @apheris_AI reports that high-quality interface predictions rose from 35.6% to 52.1%, while correct ligand poses increased from 28.9% to 46.8%.
https://t.co/UZY1f5X5sw
Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬
https://t.co/uNrxaa7z6R
Ride Therapeutics has secured up to $7.3M from @CF_Foundation to develop nonviral carriers for delivering genetic medicines to the lungs. Its AI-powered Molecular Logistics platform will advance both IV and inhaled delivery approaches.
https://t.co/IYCypslIv6
Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬
https://t.co/uNrxaa71hj
Partillion Bioscience has secured a two-year, $2.1M @NIH SBIR award to scale Cell-Cell-seq toward datasets of up to 1M cell pairs. The Nanovial-based workflow connects cell interactions and functional outputs with sequencing data.
https://t.co/5fBeHzOrNR
Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬
https://t.co/uNrxaa71hj
@TempusAI is building a research platform linking 100,000 whole genomes with longitudinal clinical outcomes, imaging and pathology.
Designed for AI model development, the dataset has a longer-term goal of reaching 1M genomes.
https://t.co/hwmWXByzLE
Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬
https://t.co/uNrxaa71hj
Five @UCBerkeley leaders have been nominated for the inaugural UC Regents Innovation Awards. Their work spans CRISPR therapies, biotech, topical biologics, startup ecosystems and semiconductor design automation.
https://t.co/LgHDoTSuJw
Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬
https://t.co/uNrxaa71hj
What makes a biological target worth drugging?
@theorema_ai has launched Causal Disease Models across 15 diseases, combining human-cell data, genetics, perturbations and clinical results to evaluate targets, uncover overlooked biology and identify new indications.
https://t.co/PcLT08vAVF
Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬
https://t.co/uNrxaa7z6R
@WatchmakerGeno1 is expanding in Boulder with a roughly 100,000-square-foot manufacturing campus expected to more than double capacity and create hundreds of Colorado jobs. The site is scheduled to open in the second half of 2027.
https://t.co/I60p0Y8uAb
Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬
https://t.co/uNrxaa7z6R
AI misuse is shifting from chatbot assistance to operational orchestration.
@AnthropicAI says it disrupted campaigns spanning cyberattacks, surveillance, influence operations, fraud, biological misuse, weapons development and model distillation.
https://t.co/KGuQAqUjrE
Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬
https://t.co/uNrxaa7z6R
NunaBio has secured @innovateuk funding through the Biomedical Catalyst to advance its DNA manufacturing technology. Its platform is designed to address challenges involving complex sequences, production scale and access.
https://t.co/5fBeHzOZDp
Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬
https://t.co/uNrxaa7z6R